

**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**

**EIP<sub>LLC</sub>**

**EIP<sub>LLC</sub>**

**Bacteriophage and Probiotics  
Used for Infection Prevention in  
Healthcare Settings:**  
**A Work in Progress**

**Lynne Schulster, PhD, M(ASCP), CMIP**  
**Environmental Infection Prevention, LLC**



**Hosted by Paul Webber**  
**paul@webbertraining.com**

[www.webbertraining.com](http://www.webbertraining.com)

August 26, 2021

**EIP<sub>LLC</sub>**

**EIP<sub>LLC</sub>**

## **Topics for Today**

- **Novel uses for bacteriophage viruses in health care**
- **Focus on use of bacteriophage for infection prevention purposes**
- **Recent research on this topic and the use of probiotics in cleaning solutions**
- **Benefits and limitations**
- **General comments about this approach to management of surface bioburden**
- **Don't forget the Chain of Infection**

2

**Hosted by Paul Webber paul@webbertraining.com**  
**www.webbertraining.com**

**EIP<sub>LLC</sub>**

**EIP<sub>LLC</sub>**

## **Bacterial Viruses**

**Bacteriophages – an extremely diverse group of viruses, particle structure has different forms**

- All bacteria can be infected, but phage generally target specific bacteria
- Can be lytic or lysogenic re: release of newly made virus
- Can pick up genetic material from its host, serves to transfer genetic information from one cell to another
- Lacks the capability to infect eukaryotic cells




Photo source: NIAID, NIH

3

**EIP<sub>LLC</sub>**

**EIP<sub>LLC</sub>**

## **Novel Uses for Bacteriophage**



- Phage therapy
- Vaccine carriers
- Gene delivery
- Food preservation and safety
- Biofilm control
- Surface disinfection

**An extensive review on these topics can be found in:**

**Harada LK, etal. Biotechnological applications of bacteriophages: State of the art. *Microbiol Res* 2018; 212-213:38-58**

4

**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**



## The Attack on the Biofilm!

- Some bacteriophage have polysaccharide depolymerases located in the tail structure
  - Hydrolytic enzymes disperse into the biofilm matrix
- Some phage have lytic enzymes VAPGHs, and double-stranded phages have endolysins
  - Create a hole in the bacterial cell wall
  - Phage DNA enters the bacterial cell, initiates infection
- Enzymatic degradation of the biofilm matrix
- Bacterial cell lysis and release of progeny bacteriophage
- Residual biofilm material now easier to remove

Source: Gutiérrez D, et al. Bacteriophages as weapons against bacterial biofilms in the food industry. *Front Microbiol* 2016; 7: 825 doi: 10.3389/fmicb.2016.00825

7

**Is the successful use of bacteriophage for control/removal of contamination in food industries transferrable for use in healthcare venues?**

**It's a work in progress...**

8


## Focus on Use of Bacteriophage for Hard Surface Cleaning and Sanitization

- Goal is to reduce and/or eliminate bacterial pathogens from a surface
- Bacteriophages have specific bacterial targets (i.e., a “one size fits all” approach requires a cocktail of multiple different bacteriophages...)
- Is the end result “sanitization” or “disinfection?”
- Current interests focus on reduction of antibiotic resistant bacteria in hopes of reducing healthcare-acquired infections (HAIs)

9

## First Phase: Proof of Concept

- Hospital isolates of antibiotic-resistant bacteria
- Surface materials tested: ceramic, glass, plastic
- 100 CFU applied to 24 cm<sup>2</sup>
- Specific phages in PBS, multiplicity of infection (MOI) 1000:1
- Sample times: 0, 1, 3, 6, 24 hours
- RODAC plates



D'Accolti, et al. *Infection Drug Resistance* 2018; 11: 1015-1026

10

EIP<sub>LLC</sub>
EIP<sub>LLC</sub>

### Reduction Effect: Bacteriophages Added to Probiotic Cleaning Solution

- *S. aureus*: 100 CFU added to 24 cm<sup>2</sup> of ceramic sink surface, let dry
- Used a combination of a phage/probiotic cleaning solution
- Duplicate samples from three independent experiments
- RODAC plates

Percentage of Bacterial Survivors

Post treatment	CTR	PCHS	Phages	PCHS + phages
1 hr	100	78	10	5
1 day	100	72	8	6
3 days	100	48	30	2
15 days	100	18	42	2

11

D'Accolti, et al. *Infection Drug Resistance* 2018; 11: 1015-1026

EIP<sub>LLC</sub>
EIP<sub>LLC</sub>

### Second Phase: Small Area *in situ* Evaluation of *S. aureus* Reduction Using Phage/Probiotic Cleaning Solution

- *S. aureus* load in bathrooms determined prior to test
- Mean starting level of contamination: 3.7 X 10<sup>4</sup> CFU/m<sup>2</sup>
- Floor, sink, shower plate
- Daily phage application by nebulization
- RODAC plates

(A) Staphylococcal contamination (bathrooms)

Sampling time (days)	PCHS+Phages	PCHS
T0	100	100
T1	10	95
T3	25	120
T5	10	70
T7	5	65
T9	15	80
T10	25	100
T11	65	75
T14	10	125
T16	5	120
T18	2	75

12

D'Accolti, et al. *Microbial Biotechnol* 2019; 12: 742-751

## Benefits and Limitations

- Bacteriophages specific for a bacterium (e.g., *S. aureus*) were able to inactivate/destroy their targets regardless of antibiotic-resistant status
- The lytic effect was rapid (previous studies by the research group indicated that 10 minutes was an effective contact time)
- Probiotic cleaning solutions need a long time to achieve a stable decrease in pathogens



13

## Probiotic Cleaning Solution Without Bacteriophage: What Impact on HAI Incidence Rates?

- Multicenter study of internal medicine units' patients in 6 hospitals in Italy over 18 months
  - One of the 6 hospitals served as a control hospital for > 6 months
- 2 study periods: pre-intervention (normal cleaning processes for terminal cleaning) and intervention (use PCHS cleaning solution with *Bacillus* sp. spores instead of conventional cleaners)
- HAI incidence was measured in both periods
- Surface sampling for bioburden determination
- HAIs observed: UTI, BSI, systemic clinical sepsis, gastrointestinal infection, skin/soft tissue infection, respiratory infection


14

**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**





**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**



**EIP<sub>LLC</sub>** **EIP<sub>LLC</sub>**

**Would an Aerosolization Method for Dispersing Bacteriophage be Suitable for this Purpose?**

18

## Taiwan Study of Aerosolization of Bacteriophage Targeting CR-AB

- Large Taiwan hospital, 945 beds
- 14 month Baseline period, and 8 month Intervention period
- 264 cases of carbapenem-resistant *Acinetobacter baumannii* (CR-AB) recorded (191 in baseline period, 73 in intervention period)
- Mean percentage of CR-AB isolation dropped to 46.07% from 87.76%
- Rates of CR-AB acquisition dropped to 5.11/1000 patient-days from 8.57/1000 patient-days (p=0.0029)

Ho Yu-Huai, et al. PLOS One 2016; doi:10.1371/journal.pone.0168380

19


## Cleaning Solution Details

- Baseline period:
  - The conventional cleaning solutions used were a 1:100 dilution of chlorine bleach (0.06%) applied to larger surfaces, and 75% alcohol applied to small surfaces
- Intervention period:
  - After routine terminal cleaning, selected bacteriophage ( $10^7$  PFU/mL) in 500 mL was aerosolized by an ultrasonic humidifier, producing a cool fog suitable for a 27 cubic meter space
  - Hospital had a panel of 24 bacteriophage, matched the incoming patient's CR-AB bacterial isolate to a specific phage
  - CR-AB was transferred into the room after the aerosolization was completed and the phage had settled
  - Phage titer on surfaces after settling:  $5.5 \times 10^4$  PFU/cm<sup>2</sup>


Ho Yu-Huai, et al. PLOS One 2016; doi:10.1371/journal.pone.0168380

20

**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**



21



22

## General Comments

- The focus on destroying targeted antibiotic-resistant bacteria is possible with this approach
- However, the bioburden on hard surfaces in healthcare facilities can be a complex mixture of bacteria, viruses, fungi
- Has potential build-up of organic matter on surfaces treated with phage/probiotic cleaning solutions been addressed?
- Current standard for surfaces in healthcare facilities is cleaned and disinfected as appropriate
- Is this approach to cleaning surfaces in healthcare facilities envisioned for widespread use in the facility or will it be limited to contact isolation areas?

23

## Chain of Infection (COI)



- Virulent pathogen:
  - Bacteria, fungi, viruses, parasites
- Sufficient number of pathogen:
  - Infectious dose
- Mode of transmission:
  - Contact, droplet, airborne, fecal/oral, indirect
- Portal of entry:
  - Broken skin, mucous membrane, respiratory tract, ingestion
- Susceptible host:
  - Age, immunity, medical conditions

Other possible links include reservoir, portal of exit

24

**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**

**EIP<sub>LLC</sub>**

**EIP<sub>LLC</sub>**

## **Thank You!**

**Lynne Schulster, PhD, M(ASCP), CMIP**  
**Environmental Infection Prevention, LLC**  
**Lm.schulster@att.net**

[www.webbertraining.com/schedulep1.php](http://www.webbertraining.com/schedulep1.php)

*(FREE Teleclass)*  
September 16, 2021 [ANTIMICROBIAL RESISTANCE AND INFECTION PREVENTION - WE HAVE MET THE ENEMY AND HE IS US](#)  
Speaker: **Prof. Allison McGeer**, Sinai Health System, University of Toronto

*(FREE South Pacific Teleclass - Broadcast live from the New Zealand Infection Prevention and Control Nurses College conference)*  
September 16, 2021 [UNDERSTANDING THE SCIENCE BEHIND AOTEAROA NEW ZEALAND'S COVID-19 RESPONSE](#)  
Speaker: **Prof. Michael Baker**, University of Otago, New Zealand

Live broadcast sponsored by Schulke

**schulke** -†

September 23, 2021 [TRIDEMICS OF INFLUENZA, COVID, AND NOW RSV](#)  
Speaker: **Prof. Robert T. Ball**, Medical University of South Carolina

Hosted by Paul Webber [paul@webbertraining.com](mailto:paul@webbertraining.com)  
[www.webbertraining.com](http://www.webbertraining.com)

**Bacteriophage and Probiotics Used for Infection Prevention in Healthcare Settings**  
**Dr. Lynne Schulster, Environmental Infection Prevention, LLC**  
**A Webber Training Teleclass**

Thanks to Teleclass Education  
**PATRON SPONSORS**



[diversey.com](http://diversey.com)



[virox.com](http://virox.com)



[gamahealthcare.com](http://gamahealthcare.com)



[gojo.com](http://gojo.com)



[who.int/infection-prevention/en](http://who.int/infection-prevention/en)

Hosted by Paul Webber [paul@webbertraining.com](mailto:paul@webbertraining.com)  
[www.webbertraining.com](http://www.webbertraining.com)